Medicare Advantage Beneficiaries Have Higher Risk of Death After Cancer Surgeries
Patients with Medicare Advantage insurance plans have an increased risk of death after certain cancer surgeries, a study suggests.
All articles by Andrea S. Blevins Primeau, PhD, MBA
High Rate of Actionable Genetic Variants Found in Colorectal Cancer Patients
Multigene panel testing in a large cohort of patients with colorectal cancer revealed a high rate of clinically actionable genetic variants.
Kaposi Sarcoma Incidence Increasing in Black Men, Decreasing in White Men
The incidence of Kaposi sarcoma is increasing among Black men and decreasing among White men in the United States, a study suggests.
Barriers to Access Do Not Fully Explain Disparities in Ovarian Cancer Treatment
Non-Hispanic Black patients are less likely than Hispanic or non-Hispanic White patients to receive guideline-recommended treatment for ovarian cancer.
Predicting Outcomes in NSCLC Patients Treated With Immunotherapy or Immunochemotherapy
Researchers have identified factors associated with survival outcomes in NSCLC patients treated with immunotherapy or immunochemotherapy.
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Adjuvant Abemaciclib Improves iDFS, DRFS in High-Risk Early Breast Cancer
Adding abemaciclib to adjuvant endocrine therapy improves outcomes in patients with high-risk early breast cancer, data suggest.
Isatuximab Plus RVd Dubbed New Standard Care in Newly Diagnosed Multiple Myeloma
Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.
No Difference in OS With Margetuximab vs Trastuzumab in HER2+ Breast Cancer
Margetuximab does not provide an overall survival benefit over trastuzumab in patients with previously treated, HER2-positive breast cancer, a phase 3 trial suggests.
Oncology Hospitalists Improve Readmission Rates and Discharge to Hospice
The use of oncology hospitalists can reduce readmission rates and improve discharge to hospice, a study suggests.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...